Correction

Correction to: Bioavailability Enhancement of Olmesartan Medoxomil Using Hot-Melt Extrusion: *In-Silico*, *In-Vitro*, and *In-Vivo* Evaluation

Pankaj Jadhav,¹ Vinod Gokarna,² Vineeta Deshpande,³ and Pradeep Vavia^{1,4}

Published online 2 October 2020

Correction to: AAPS PharmSciTech volume 21, Article number: 254 (2020).

<https://doi.org/10.1208/s12249-020-01780-3>

During production, the supplemental file “Trajectory analysis of 5ns MD simulation of VA-64 and OLM.mpeg”, as well as the “RunNo and Serial numbers”, for Tables III and VII respectively, were inadvertently omitted from the published article (Tables I, II, III, IV, V, VI, and VII).

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at <https://doi.org/10.1208/s12249-020-01780-3>

¹ Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, University under Section 3 of UGC Act – 1956, Elite Status and Center of Excellence – Government of Maharashtra, TEQIP Phase II Funded, Mumbai, Matunga (E) 400019, India.

² Don Bosco Institute of Technology, Mumbai, Kurla (W) 400070, India.

³ Department of Physics, Institute of Chemical Technology, University under Section 3 of UGC Act – 1956, Elite Status and Center of Excellence – Government of Maharashtra, TEQIP Phase II Funded, Mumbai, Matunga (E) 400019, India.

⁴ To whom correspondence should be addressed. (e-mail: pr.vavia@ictmumbai.edu.in)

Table I. Variables and Their Levels for Experimental Design

Variables	Levels				
	-1.682 ($-\alpha$)	-1	0	1	1.682 (α)
Independent variables/factors					
X ₁ : Drug concentration (%w/w)	6.59	10	15	20	23.41
X ₂ : Extrusion temperature (°C)	157	160	165	170	173
X ₃ : Screw speed (RPM)	74.43	100	137.5	175	200.57
Dependent variable/response	Constrains				
Y: % drug release in the first 10 min	Maximize				

Table II. Solubility Parameter Values of Formulation Components and Miscibility Prediction

Compound	δ Solubility parameter	$\Delta\delta = (\delta_{OLM} - \delta_{Carrier})$	Miscibility
OLM	21.07 (MD simulation)	–	–
VA-64	20.53 (Piccinni et al., 2016)	0.54	Miscible
Soluplus	19.90 (Piccinni et al., 2016)	1.17	Miscible
$\Delta\delta$ is difference in solubility parameters between drug and carrier			

Table III. Central Composite Design Run

Run No	Independent variables			Dependent variable/response
	X ₁ -drug concentration (%w/w)	X ₂ -extrusion temperature (°C)	X ₃ -screw speed (RPM)	Y -% drug release in the first 10 min
1	10	160	100	83.2
2	20	160	100	74.2
3	10	170	100	86.9
4	20	170	100	66.5
5	10	160	175	79.99
6	20	160	175	61.9
7	10	170	175	82.3
8	20	170	175	44.3
9	6.59	165	137.5	73.8
10	23.41	165	137.5	57.8
11	15	157	137.5	94.4
12	15	173	137.5	59.6
13	15	165	74.43	93.01
14	15	165	200.57	89.7
15	15	165	137.5	83.5
16	15	165	137.5	84.9
17	15	165	137.5	84.1
18	15	165	137.5	86.6
19	15	165	137.5	82.8
20	15	165	137.5	87.2

Table IV. ANOVA for Response Surface Quadratic Model

Source	Sum of squares	df	Mean square	F value	p-value Prob > F	
Model	2867.08	9	318.56	6.61	0.0034	Significant
X ₁ -drug concentration	924.51	1	924.51	19.18	0.0014	
X ₂ -temperature	444.49	1	444.49	9.22	0.0125	
X ₃ -screw speed	168.48	1	168.48	3.50	0.0911	
X ₁ X ₂	122.70	1	122.70	2.55	0.1417	
X ₁ X ₃	89.04	1	89.04	1.85	0.2040	
X ₂ X ₃	15.65	1	15.65	0.32	0.5814	
X ₁ ²	887.82	1	887.82	18.42	0.0016	
X ₂ ²	217.63	1	217.63	4.51	0.0595	
X ₃ ²	20.21	1	20.21	0.42	0.5318	
Residual	482.01	10	48.20			
Lack of fit	482.01	5	96.40			
Pure error	0.000	5	0.000			
Cor total	3349.09	19				

Table V. Percent Crystallinity Data

Sr. No.	Sample description	% Crystallinity
1	OLM	52.72
2	VA-64	7.25
3	PM	20.88
4	OLMEXT	5.96

Table VI. Pharmacokinetic Parameters

Parameters	OLM	OLM EXT
C _{max} (µg/mL)	1.2396	3.3047
T _{max} (h)	2	0.5
AUC ₀₋₂₄ (µg/mL*h)	7.2344	14.5842
t _{1/2} (h)	8.65	5.05
K _e (h ⁻¹)	0.08018	0.1372
Cl (mg)/(µg/ml)/h	0.26956	0.15861
Vd (mg)/(µg/ml)	3.36205	1.156152
MRT _{0-∞} (h)	13.9144	6.9345
Relative bioavailability (%)	201.59	

Table VII. Stability Evaluation of OLM EXT

Sr. No.	Test	Stability period (months)		
		0	3	6
1	Appearance	Transparent extrudes	Transparent extrudes	Transparent extrudes
2	Assay	99.17%	98.87%	97.78%
3	% crystallinity	6.01%	5.98%	6.05%